LABD

Direxion Daily S&P Biotech Bear 3X Shares (LABD) | Rumor.io

Direxion Daily S&P Biotech Bear 3X Shares

LABD

Attention (50-day avg)0.01%

Attention rank (50-day avg)#642

Bullish sentiment (50-day avg)44%

Price to earnings ratio0

Net assets0

Expense ratio0.01%

Social

What share of all ETF conversation is about LABD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0.01	0.01% +0	0.01% +0	0% 0

Aug 19

The $LABD price is expected to move lower as the market reaches oversold territory, and the author is buying more shares.
The author is adding to their position in $LABD as the price of $XBI, which holds a significant weight of $LABD, is expected to hit or approach the 165-166 level.
The author believes $LABD is a good long-term investment opportunity, citing the potential for $XBI to test all-time highs around $170, and the author's entry point is around $6.40.

Generated by AI

Sentiment

Of the messages about LABD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	85.71% +85.71	50% +23.91	46.23% +4.8	41.18% -18.47
Bearish	14.29% -85.71	50% -23.91	53.77% -4.8	58.82% +18.47

Bullish· Oct 8

The asset has shown a significant price swing, with a 40-point swing from $63.78 to $103.51 in the past, and a similar swing from $66.66 to $106.50, which could indicate a potential capitulation day.
The trend line of the day is at risk of being broken, with the asset close to a significant level, making it a potentially attractive entry point.
The biotech sector is showing signs of improvement, with Mizuho commenting that the sector is looking better than it has in years, which could be a positive indicator for the asset.

Bearish· Aug 19

The asset has seen significant declines, with one user adding to their position at $6.40, another at $6.09, and a third at $5.99.
Some users believe the asset's price will continue to fall, with one user predicting a bottom near $5.85 and another expecting a pump to $8.25.
Others are cautiously optimistic, with one user noting that the asset's technicals are uncertain and another stating that there's no reason to be bearish until past all-time highs.

Generated by AI

Topics

Of the messages about LABD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Technical Analysis	100%	83.33%	93.94%	90.89%
Macro	0%	16.67%	6.06%	9.11%

Macro· Feb 29

The PCE inflation rate came in at 0.4%, with the highest increase in a year, and 3 consecutive months of increases.
The author expects a 13-18% correction in the biotech sector, citing historical precedents, and believes this will be a "sell the news" event.
The author is concerned that the Fed will ignore the high inflation rate and instead focus on the narrative that it is a "bump" in the road, and that this will lead to further price increases in rate-sensitive sectors.

Technical Analysis· Aug 19

The current price of $LABD is being used as a buy point, with the author purchasing more shares at $6.09, $6.40, and $6.63.
The author is anticipating a potential price increase, with one post suggesting a target price of $170 for XBI and another citing a potential price decrease to $6.3.
The author is primarily focusing on the technical analysis of the stock, with many posts discussing the current price, potential price targets, and the author's buying and selling strategies.

Generated by AI

Community

Of the messages about LABD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	98.04%	92.81%	93.87%
Newcomers	0%	1.96%	7.19%	6.13%

Regulars· Aug 19

XBI is expected to hit the 165-166 level today or this week, prompting a potential buy of LABD near 6.45-6.55.
The regular is preparing for a double top test in XBI within the next week, and is adding/doubling down on LABD.
XBI's 52-week high is being tested, and there's a good chance it will break above 164-165, potentially leading to a test of all-time highs around 170+.

Newcomers· Jul 21

Newcomers are taking long positions in $LABD, a bear 3x ETF, in hopes of profiting from the decline of the biotech sector.
Some traders are reevaluating their underperformance idea for $LABD, as the sector has not yet broken down despite some losses.
The price action for $LABD is being monitored for a potential reversal, with some traders looking for a "gravestone doji" formation to signal a significant turn.

Generated by AI

Also Discussed

Investors talking about LABD also mention

#	Name	Attention
1	Direxion Daily S&P Biotech Bull 3X SharesLABU	0.01%+0.01
2	SPDR S&P Biotech ETFXBI	0.42%+0.08
3	Direxion Daily Technology Bear 3X SharesTECS	0%0
4	iShares Biotechnology ETFIBB	0.01%0
5	Direxion Daily Semiconductor Bear 3X SharesSOXS	0.14%-0.04
6	Direxion Daily Energy Bear 2X SharesERY	0%new
7	Direxion Daily Gold Miners Index Bull 2X Shares ETFDUST	0%0
8	Direxion Daily Junior Gold Miners Index Bear 2X SharesJDST	0.02%new
9	Direxion Daily Gold Miners Index Bull 2X SharesNUGT	0%0
10	Direxion Daily S&P 500 Bear 3X SharesSPXS	0%+0

Direxion Daily S&P Biotech Bear 3X Shares

The Direxion Daily S&P Biotech Bear 3X Shares is an exchange-traded fund designed to provide triple inverse exposure to the S&P Biotechnology Select Industry Index. This asset aims to achieve 300% of the inverse daily performance of the specified index, which tracks the biotechnology sector's performance, encompassing companies focused on areas such as pharmaceuticals, genetic research, and medical devices. Its primary function is to offer investors the opportunity to profit from declines in the biotechnology sector over short-term periods, employing a leveraged strategy to amplify inverse returns. Notable features of this ETF include its focus on inverse leverage and its utility in tactical trading during periods of anticipated downturns in the biotechnology industry. However, due to its leveraged nature, it is typically not intended for long-term investment and is instead suited for experienced investors who aim to hedge against sectorial risk or capitalize on short-term market pullbacks. Its role in the financial market includes offering liquidity and strategic flexibility for traders looking to navigate or speculate on volatility within the biotech sector.

Location

United States

Social

What share of all ETF conversation is about LABD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0.01	0.01% +0	0.01% +0	0% 0

Aug 19

The $LABD price is expected to move lower as the market reaches oversold territory, and the author is buying more shares.
The author is adding to their position in $LABD as the price of $XBI, which holds a significant weight of $LABD, is expected to hit or approach the 165-166 level.
The author believes $LABD is a good long-term investment opportunity, citing the potential for $XBI to test all-time highs around $170, and the author's entry point is around $6.40.

Generated by AI

Sentiment

Of the messages about LABD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	85.71% +85.71	50% +23.91	46.23% +4.8	41.18% -18.47
Bearish	14.29% -85.71	50% -23.91	53.77% -4.8	58.82% +18.47

Bullish· Oct 8

The asset has shown a significant price swing, with a 40-point swing from $63.78 to $103.51 in the past, and a similar swing from $66.66 to $106.50, which could indicate a potential capitulation day.
The trend line of the day is at risk of being broken, with the asset close to a significant level, making it a potentially attractive entry point.
The biotech sector is showing signs of improvement, with Mizuho commenting that the sector is looking better than it has in years, which could be a positive indicator for the asset.

Bearish· Aug 19

The asset has seen significant declines, with one user adding to their position at $6.40, another at $6.09, and a third at $5.99.
Some users believe the asset's price will continue to fall, with one user predicting a bottom near $5.85 and another expecting a pump to $8.25.
Others are cautiously optimistic, with one user noting that the asset's technicals are uncertain and another stating that there's no reason to be bearish until past all-time highs.

Generated by AI

Topics

Of the messages about LABD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Technical Analysis	100%	83.33%	93.94%	90.89%
Macro	0%	16.67%	6.06%	9.11%

Macro· Feb 29

The PCE inflation rate came in at 0.4%, with the highest increase in a year, and 3 consecutive months of increases.
The author expects a 13-18% correction in the biotech sector, citing historical precedents, and believes this will be a "sell the news" event.
The author is concerned that the Fed will ignore the high inflation rate and instead focus on the narrative that it is a "bump" in the road, and that this will lead to further price increases in rate-sensitive sectors.

Technical Analysis· Aug 19

The current price of $LABD is being used as a buy point, with the author purchasing more shares at $6.09, $6.40, and $6.63.
The author is anticipating a potential price increase, with one post suggesting a target price of $170 for XBI and another citing a potential price decrease to $6.3.
The author is primarily focusing on the technical analysis of the stock, with many posts discussing the current price, potential price targets, and the author's buying and selling strategies.

Generated by AI

Community

Of the messages about LABD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	98.04%	92.81%	93.87%
Newcomers	0%	1.96%	7.19%	6.13%

Regulars· Aug 19

XBI is expected to hit the 165-166 level today or this week, prompting a potential buy of LABD near 6.45-6.55.
The regular is preparing for a double top test in XBI within the next week, and is adding/doubling down on LABD.
XBI's 52-week high is being tested, and there's a good chance it will break above 164-165, potentially leading to a test of all-time highs around 170+.

Newcomers· Jul 21

Newcomers are taking long positions in $LABD, a bear 3x ETF, in hopes of profiting from the decline of the biotech sector.
Some traders are reevaluating their underperformance idea for $LABD, as the sector has not yet broken down despite some losses.
The price action for $LABD is being monitored for a potential reversal, with some traders looking for a "gravestone doji" formation to signal a significant turn.

Generated by AI

Direxion Daily S&P Biotech Bear 3X Shares

Social

Aug 19

Sentiment

Bullish· Oct 8

Bearish· Aug 19

Topics

Macro· Feb 29

Technical Analysis· Aug 19

Community

Regulars· Aug 19

Newcomers· Jul 21

Also Discussed

Direxion Daily S&P Biotech Bear 3X Shares

Company Information

Location

Also Discussed

Social

Aug 19

Sentiment

Bullish· Oct 8

Bearish· Aug 19

Topics

Macro· Feb 29

Technical Analysis· Aug 19

Community

Regulars· Aug 19

Newcomers· Jul 21